Omni Bio is an emerging biopharmaceutical company that has licensed therapies currently in development that have the potential to address large, unmet diseases and generate substantial commercialization potential.
Our core strategy is based on licensing issued and pending patents that cover new uses for an existing FDA-approved drug, Alpha-1 antitrypsin (AAT). We intend to leverage sponsored research, collaborations with existing AAT manufacturers, and licensed patents for the development and commercialization of AAT in additional indications.
5350 South Roslyn
Greenwood Village, CO 80111